Population pharmacokinetic model for the characterization of magnesium sulfate toxicity in pregnant women with preeclampsia
pharmacokinetics, preeclampsia, magnesium sulfate, drug adverse reaction, pregnancy.
OBJECTIVES: To develop a population pharmacokinetic model considering individual patient characteristics aimed at an improved dose definition for the prevention of toxicity in pregnant women with pre-eclampsia (PE). METHODOLOGY: Prospective cohort of patients with preeclampsia administered magnesium sulfate. The patients (n = 111) received 4 g of magnesium sulphate intravenously followed by the hourly infusion of 1 g during 24 hours. Serum magnesium levels were measured in blood samples obtained before administration and 2, 6, 12 and 18 hours after the initial dose and 4 h after the end of the administration. Adverse reactions to magnesium sulphate were investigated through active search. Population pharmacokinetic parameters were estimated using the Monolix software® 2018 Suite (Lixoft®, Antony, France). Demographic, clinical and laboratory variables were tested for significance. RESULTS: A 1-compartment model was adopted. Patients with a lower body weight and higher serum creatinine are more susceptible to magnesium toxicity. CONCLUSION: The population pharmacokinetics model proposes the adoption of individualized dosing schemes of magnesium sulfate based on creatinine and body weight in order to prevent toxicity manifestations.